Use of data from registered clinical trials to identify gaps in health research and development

Viergever, Roderik F.; Terry, Robert F; Karam, Ghassan

doi:10.2471/blt.12.114454

Cited by 38 publications

(55 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 In addition, we found fewer registered trials for communicable, maternal, perinatal, and nutritional conditions (22% of trials; 71% of the global burden) than for noncommunicable diseases (74% of trials; 21% of the global burden). This disparity is also present in adult trials, 5 but it is larger for pediatric trials, potentially reflecting that the lack of health R&D for populations in developing countries disproportionately affects children.…”

mentioning

confidence: 96%

“…In our own study, the numbers of trials recruiting in low- Numbers are based on a 5% sample of all interventional and actively recruiting trials on the WHO ICTRP taken on August 10, 2012. 5 The total number of trials in the sample was 2381. For 2254 trials, age information was available.…”

mentioning

confidence: 99%

“…Particularly, our knowledge of what health research is being conducted globally, where it is being conducted, by whom, and how is limited. 4,5 Mapping the health R&D landscape requires a triangulation of different sources of information on R&D inputs (eg, investments), R&D processes (eg, clinical trials), and R&D outputs (eg, publications or products). 4,5 Recently, we conducted an evaluation of registered clinical trials on the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP).…”

mentioning

confidence: 99%

“…4,5 Mapping the health R&D landscape requires a triangulation of different sources of information on R&D inputs (eg, investments), R&D processes (eg, clinical trials), and R&D outputs (eg, publications or products). 4,5 Recently, we conducted an evaluation of registered clinical trials on the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP). 5 Previous analyses have shown a discrepancy between the pediatric disease burden and the amount of clinical trial research devoted to pediatric populations.…”

mentioning

confidence: 99%

“…4,5 Recently, we conducted an evaluation of registered clinical trials on the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP). 5 Previous analyses have shown a discrepancy between the pediatric disease burden and the amount of clinical trial research devoted to pediatric populations. 2 Our analysis confirms this finding for low-and middle-income countries but not for high-income countries (Table 1).…”

mentioning

confidence: 99%

See 4 more Smart Citations

Finding Better Ways to Fill Gaps in Pediatric Health Research

Viergever

Rademaker

2014

Pediatrics

View full text Add to dashboard Cite

mentioning

confidence: 96%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Finding Better Ways to Fill Gaps in Pediatric Health Research

Viergever

Rademaker

2014

Pediatrics

View full text Add to dashboard Cite

Does global drug innovation correspond to burden of disease? The neglected diseases in developed and developing countries

2018

View full text Add to dashboard Cite

Although it is commonly argued that there is a mismatch between drug innovation and disease burden, there is little evidence on the magnitude and direction of such disparities. In this paper, we measure inequality in innovation, by comparing research and development activity with population health and gross domestic product data across 493 therapeutic indications to globally measure: (a) drug innovation, (b) disease burden, and (c) market size. We use concentration curves and indices to assess inequality at two levels: (a) broad disease groups and (b) disease subcategories for both 1990 and 2010. For some top burden disease subcategories (i.e., cardiovascular and circulatory diseases, neoplasms, and musculoskeletal disorders), innovation is disproportionately concentrated in diseases with high disease burden and large market size, whereas for others (i.e., mental and behavioral disorders, neonatal disorders, and neglected tropical diseases) innovation is disproportionately concentrated in low burden diseases. These inequalities persisted over time, suggesting inertia in pharmaceutical research and development in tackling the global health challenges. Our results confirm quantitatively assertions about the mismatch between disease burden and pharmaceutical innovation in both developed and developing countries and highlight the disease areas for which morbidity and mortality remain unaddressed.

show abstract

Patient income and health innovation

Moradpour

Hollis

2020

Health Economics

View full text Add to dashboard Cite

This study analyzes the relationship between the number of clinical trials in a disease area, the health losses from that disease, and the average income of people suffering from it. Average patient income appears strongly predictive of the number of clinical trials, whether funded by industry or not. We are able to precisely estimate the relationship between income and the number of trials and to identify both (a) the specific diseases that appear to be underfunded relative to their harm to human health and (b) the amount of additional funding required to bring innovation investment up to the present average.

show abstract

Use of data from registered clinical trials to identify gaps in health research and development

Cited by 38 publications

References 36 publications

Finding Better Ways to Fill Gaps in Pediatric Health Research

Finding Better Ways to Fill Gaps in Pediatric Health Research

Does global drug innovation correspond to burden of disease? The neglected diseases in developed and developing countries

Patient income and health innovation

Contact Info

Product

Resources

About